Soluble Fas Ligand: Is It a Critical Mediator of Toxic Epidermal Necrolysis and Stevens–Johnson Syndrome?

A marker for Stevens–Johnson syndrome

2004 • 1,685 citations

Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin

1999 • 867 citations

Drug Specific Cytotoxic T-Cells in the Skin Lesions of a Patient with Toxic Epidermal Necrolysis

2002 • 297 citations

Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome Are Induced by Soluble Fas Ligand

2003 • 288 citations

A Novel Polymorphic CAAT/Enhancer-Binding Protein β Element in theFasLGene Promoter Alters Fas Ligand Expression: A Candidate Background Gene in African American Systemic Lupus Erythematosus Patients

2003 • 207 citations

Macrophages and tumor necrosis factor alpha in toxic epidermal necrolysis

1994 • 154 citations

FASL –844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer

2005 • 120 citations

Macrophages and Tumor Necrosis Factor a in Toxic Epidermal Necrolysis

1994 • 104 citations

Soluble FAS Ligand: A Discriminating Feature between Drug-Induced Skin Eruptions and Viral Exanthemas

2006 • 75 citations

Clinical significance of serum soluble Fas ligand in patients with acute self-limited and fulminant hepatitis.

1998 • 19 citations